Actelion Gets Auxilium Drug Rights - Analyst Blog
February 27 2012 - 6:00AM
Zacks
European biotechnology company Actelion Ltd.
(ALIOF) recently acquired exclusive commercialization rights to
Auxilium Pharmaceuticals, Inc.’s
(AUXL) Xiaflex for the treatment of Dupuytren’s
contracture and Peyronie’s disease in Canada, Australia, Brazil and
Mexico.
Xiaflex is approved in the US and European Union and is under
review in Canada for the treatrment of Dupuytren’s contracture. A
decision in Canada is expected in the second half of 2012. In
Brazil, Australia and Mexico, Actelion will file regulatory
applications over the next 12 months. For Peyronie’s disease, a
phase III trial is ongoing, top-line data fom which are expected in
the second quarter of 2012. Auxilium will be responsible for the
development of Xiaflex for Peyronie’s disease worldwide except in
Actelion’s territories, where Actelion will bear clinical
development costs, if any.
Auxilium will get an upfront payment of $10 million from
Actelion. In addition, Auxilium will also be entitled to potential
regulatory ($16 million) and sales based ($42.5 million) milestone
payments.
Dupuytren’s contracture is a fixed flexion contracture of the
hand where the fingers bend towards the palm and cannot be fully
straightened. Peyronie's Disease is a connective tissues disorder
which involves the growth of fibrous plaques in the soft tissue of
the penis.
The addition of Xiaflex will boost Actelion’s already strong
pipeline. The company’s most important pipeline candidate is
Macitentan, a follow-on compound to its drug Tracleer which is
marketed for the treatment of pulmonary arterial hypertension
(PAH). Macitentan is currently in a phase III PAH trial (SERAPHIN;
n>700). Actelion is expected to present data from the
study in the second half of this year. We believe that the SERAPHIN
results will be the most important near-term catalyst for Actelion
as it is designed to help replace Tracleer which is currently
facing intense competition from Gilead’s (GILD)
Letairis and is due to face generic competition in 2015-2017.
Our Take
Actelion’s shares carry a Zacks #5 Rank (short-term ‘Strong
Sell’ rating). We like the company’s strong pipeline with abundant
pipeline catalysts coming up in 2012. However, the poor fourth
quarter and 2011 results justify the short-term bearish outlook on
the company.
AUXILIUM PHARMA (AUXL): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2024 to Jun 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2023 to Jun 2024